Compounds > 3-cyano-6-hydroxy-4-methyl-2-pyridone
Page last updated: 2024-11-06

3-cyano-6-hydroxy-4-methyl-2-pyridone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-cyano-6-hydroxy-4-methyl-2-pyridone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID79516
CHEMBL ID3086510
SCHEMBL ID1222275
MeSH IDM000607316

Synonyms (68)

Synonym
HMS1783B09
AKOS000445810
3-cyano-2,6-dihydroxy-4-methylpyridine
2,6-dihydroxy-3-cyano-4-methylpyridine
einecs 226-639-7
1,2-dihydro-6-hydroxy-4-methyl-2-oxonicotinonitrile
3-pyridinecarbonitrile, 1,2-dihydro-6-hydroxy-4-methyl-2-oxo-
nsc 19883
3-pyridinecarbonitrile,2-dihydro-6-hydroxy-4-methyl-2-oxo-
2,6-dihydroxy-4-methyl-3-pyridinecarbonitrile ,
nsc19883
5444-02-0
nsc-19883
2,6-dihydroxy-4-methylnicotinonitrile
2,6-dihydroxy-4-methyl-pyridine-3-carbonitrile
2,6-dihydroxy-4-methyl-3-pyridinecarbonitrile, 99%
AKOS000268878
F3250-0685
AB00683647-01
AKOS002254697
2-hydroxy-4-methyl-6-oxo-1h-pyridine-3-carbonitrile
6-hydroxy-4-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile
2,6-dihydroxy-4-methylpyridine-3-carbonitrile
A15641
2,6-dihydroxy-4-methylnicotinonitrile;2,6-dihydroxy-3-cyano-4-methylpyridine
FT-0610663
STL377949
4T-0009
AM20061305
PB28990
bdbm50443010
CHEMBL3086510 ,
6-hydroxy-4-methyl-2-oxo-1,2-dihydro-pyridine-3-carbonitrile
BBL027991
2-hydroxy-5-cyano-4-methylpyrid-6-one
3-cyano-4-methyl-6-hydroxypyridone
3-cyano-6-hydroxy-4-methylpyrid-2-one
3-cyano-4-methyl-6-hydroxypyrid-2-one
DTXSID2063890
4-methyl-3-cyan-2,6-dioxypyridin
SCHEMBL1222275
mfcd00023471
SY015989
nicotinonitrile, 2,6-dihydroxy-4-methyl-
pyridine-3-carbonitrile, 2,6-dihydroxy-4-methyl-
2,6-dihydroxy-4-methyl nicotinonitrile
W-110041
3-cyano-4-methyl-2,6-pyridinediol
3-cyano-2,6-dihydroxy-4-picoline
C2620
3-cyano-6-hydroxy-4-methyl-2-pyridone
VU0607315-1
F1920-0008
AC-8289
Z57001599
3-cyano-6-hydroxy-4-methyl-2(1h)-pyridone
STL558375
6-hydroxy-5-cyano-4-methyl-2-pyridone
40401-47-6
BCP26881
HMS3741M13
CCG-274493
P10043
EN300-17738
CS-W018157
nsc-818302
nsc818302
PD128694
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thymidine phosphorylaseHomo sapiens (human)IC50 (µMol)100.00000.02001.58386.8000AID1054088
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Uridine phosphorylase 1Homo sapiens (human)Kd3.36500.02001.49956.6000AID1054083; AID1054084; AID1054085; AID1054086
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Uridine phosphorylase 1Homo sapiens (human)Kii0.48350.13000.77102.5460AID1054089; AID1054093
Uridine phosphorylase 1Homo sapiens (human)Kis0.37500.37501.02422.6100AID1054098
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
mitochondrial genome maintenanceThymidine phosphorylaseHomo sapiens (human)
angiogenesisThymidine phosphorylaseHomo sapiens (human)
pyrimidine nucleobase metabolic processThymidine phosphorylaseHomo sapiens (human)
pyrimidine nucleoside metabolic processThymidine phosphorylaseHomo sapiens (human)
chemotaxisThymidine phosphorylaseHomo sapiens (human)
signal transductionThymidine phosphorylaseHomo sapiens (human)
cell differentiationThymidine phosphorylaseHomo sapiens (human)
regulation of myelinationThymidine phosphorylaseHomo sapiens (human)
dTMP catabolic processThymidine phosphorylaseHomo sapiens (human)
regulation of transmission of nerve impulseThymidine phosphorylaseHomo sapiens (human)
regulation of gastric motilityThymidine phosphorylaseHomo sapiens (human)
nucleobase-containing compound metabolic processUridine phosphorylase 1Homo sapiens (human)
uridine catabolic processUridine phosphorylase 1Homo sapiens (human)
CMP catabolic processUridine phosphorylase 1Homo sapiens (human)
dCMP catabolic processUridine phosphorylase 1Homo sapiens (human)
cellular response to glucose starvationUridine phosphorylase 1Homo sapiens (human)
UMP salvageUridine phosphorylase 1Homo sapiens (human)
UMP catabolic processUridine phosphorylase 1Homo sapiens (human)
dTMP catabolic processUridine phosphorylase 1Homo sapiens (human)
dUMP catabolic processUridine phosphorylase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
1,4-alpha-oligoglucan phosphorylase activityThymidine phosphorylaseHomo sapiens (human)
protein bindingThymidine phosphorylaseHomo sapiens (human)
growth factor activityThymidine phosphorylaseHomo sapiens (human)
thymidine phosphorylase activityThymidine phosphorylaseHomo sapiens (human)
protein homodimerization activityThymidine phosphorylaseHomo sapiens (human)
uridine phosphorylase activityUridine phosphorylase 1Homo sapiens (human)
thymidine phosphorylase activityUridine phosphorylase 1Homo sapiens (human)
identical protein bindingUridine phosphorylase 1Homo sapiens (human)
deoxyuridine phosphorylase activityUridine phosphorylase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
cytosolThymidine phosphorylaseHomo sapiens (human)
cytosolThymidine phosphorylaseHomo sapiens (human)
nucleoplasmUridine phosphorylase 1Homo sapiens (human)
cytosolUridine phosphorylase 1Homo sapiens (human)
cytosolUridine phosphorylase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1054085Binding affinity to human recombinant UP1-R1P binary complex expressed in Escherichia coli Rosetta (DE3) at 50 uM R1P by isothermal titration calorimetric analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity.
AID1054095Time dependent inhibition of human recombinant UP1 expressed in Escherichia coli Rosetta (DE3) using URD and inorganic phosphate as substrate at 1 uM by spectrophotometric analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity.
AID1054088Inhibition of human thymidine phosphorylase2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity.
AID1054077Potentiation of 5-FU-induced cytotoxicity against human SW620 cells assessed as reduction in compound IC50 at 30 uM after 72 hrs by MTT assay relative to control2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity.
AID1054078Potentiation of 5-FU-induced cytotoxicity against human HT-29 cells assessed as reduction in compound IC50 at 30 uM after 72 hrs by MTT assay relative to control2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity.
AID1054083Binding affinity to human recombinant UP1-R1P binary complex expressed in Escherichia coli Rosetta (DE3) at 200 uM R1P by isothermal titration calorimetric analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity.
AID1054086Binding affinity to human recombinant UP1-inorganic phosphate binary complex expressed in Escherichia coli Rosetta (DE3) by isothermal titration calorimetric analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity.
AID1054084Binding affinity to human recombinant UP1-R1P binary complex expressed in Escherichia coli Rosetta (DE3) at 150 uM R1P by isothermal titration calorimetric analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity.
AID1054079Effect on 5-FU-induced cytotoxicity against human HaCaT cells at 30 uM after 72 hrs by MTT assay2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity.
AID1054096Inhibition of human recombinant UP1 expressed in Escherichia coli Rosetta (DE3) using URD and inorganic phosphate as substrate at 1 uM after 60 seconds by spectrophotometric analysis relative to control2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity.
AID1054089Uncompetitive inhibition of human recombinant UP1 expressed in Escherichia coli Rosetta (DE3) using inorganic phosphate as substrate by Lineweaver-Burk plot analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity.
AID1054093Non-competitive inhibition of human recombinant UP1 expressed in Escherichia coli Rosetta (DE3) using URD as substrate assessed as equilibrium dissociation constant for enzyme-substrate-inhibitor complex by Lineweaver-Burk plot analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity.
AID1054082Cytotoxicity against human HaCaT cells at 1 to 100 uM after 72 hrs by MTT assay2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity.
AID1054098Non-competitive inhibition of human recombinant UP1 expressed in Escherichia coli Rosetta (DE3) using URD as substrate assessed as equilibrium dissociation constant for enzyme-inhibitor complex by Lineweaver-Burk plot analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity.
AID1054081Cytotoxicity against human HT-29 cells at 1 to 100 uM after 72 hrs by MTT assay2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity.
AID1054080Cytotoxicity against human SW620 cells at 1 to 100 uM after 72 hrs by MTT assay2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.28 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
uridine
[no description available]		2.0810uridinesdrug metabolite;
fundamental metabolite;
human metabolite
dimethylacetamide
hallucinogen : Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations and other alterations of mood and thinking.. N,N-dimethylacetamide : A member of the class of acetamides that is acetamide in which the hydrogens attached to the N atom have been replaced by two methyl groups respectively. Metabolite observed in cancer metabolism.		2.1110acetamides;
monocarboxylic acid amide		human metabolite
5-benzylacyclouridine
5-benzylacyclouridine: structure given in first source. 5-benzyl-1-(2-hydroxyethoxymethyl)uracil : A pyrimidone that is uracil which is substituted by a 2-hydroxyethoxymethyl group at position 1 and a benzyl group at position 5.		2.0810hydroxyether;
primary alcohol;
pyrimidone
2,6-dihydroxypyridine
2,6-dihydroxypyridine: inhibits dihydropyrimidine dehydrogenase		2.0810dihydroxypyridine
2,6-dihydroxy-3-cyanopyridine
2,6-dihydroxy-3-cyanopyridine: inhibitor of 5-fluorouracil degradation		2.0810
ConditionIndicatedRelationship StrengthStudiesTrials
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610
Anemia, Fanconi
[description not available]		02.1310
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		02.1310